Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ardea Biosciences, a developer of small-molecule therapeutics, has initiated a Phase I/II study of RDEA119, its lead mitogen-activated ERK kinase inhibitor for the treatment of cancer, in combination with Nexavar, which is currently approved for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Subscribe to our email newsletter
Preclinical in-vitro and in-vivo studies of RDEA119 have demonstrated synergistic activity across multiple tumor types when RDEA119 is used in combination with other anticancer agents, including sorafenib.
This Phase I/II study in patients with advanced cancer will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of RDEA119 in combination with Nexavar.
Barry Quart, president and CEO of Ardea, said: “RDEA119 represents an exciting, new opportunity in cancer treatment. The synergistic activity that we have seen in preclinical studies of RDEA119 in combination with a broad range of anticancer agents suggests that RDEA119 has the potential to enhance the current standard-of-care across multiple cancer indications.”